HIV-1 Clinical Trial
— Vac09Official title:
Active Immunotherapy Against HIV During Highly Active Anti-retroviral Therapy Followed by Repeated Treatment Interruptions
In this study, the investigators evaluated a therapeutic HIV-1 DNA vaccine administered with a novel topical application method to 12 chronically HIV-infected cART treated patients. The HIV DNA plasmids used in this study encode for envelope gp160 of HIV-1 subtypes A, B and C, rev B, Gag A and B and reverse transcriptase (RT) B. The patients were randomly assigned to three groups; group 1 (n=4) were immunized six times with 0.4 mg of HIV DNA plasmids topically, group 2 (n=4) were immunized six times with 0.4 mg of HIV DNA plasmids topically and treated with 500 mg of hydroxyurea daily until visit 10, group 3 (n=4) four patients received placebo. The immunization was performed during three cycles of 7 weeks of cART followed by four weeks of therapy interruption. After the last cycle of cART the patients were maintained on a definitive treatment interruption until CD4+ T cell counts dropped below 350/ mm3 at two time points. Cellular and humoral immune responses, viral load and CD4+ T a cell count was analysed throughout the study.
Status | Completed |
Enrollment | 12 |
Est. completion date | December 2009 |
Est. primary completion date | October 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: 1. Aged between 18 and 60 years 2. Female, who is documented infertile or in menopause since at least 1 year, or male, who are willing not father a child for the duration of the study. 3. HIV infection detected by two serological and/or HIV plasma RNA tests 4. On HAART for at least 6 months with less than 50 copies/ml of plasma HIV-1 RNA at two determinations over 3 months 5. Current CD4 count above 400 6. CD4 count nadir >200 7. Viral isolate pre ART available is preferable but not mandatory 8. Willing to consider stopping HAART repeatedly. 9. Willing to conform to a low alcohol intake (maximum of one glass per day) 10. Able to tolerate didanosine and hydroxyurea 11. Willing to change their HAART to exclude NNRTI and stavudine 12. Able to give informed consent 13. Availability for follow-up for planned duration of the study Exclusion Criteria: 1. Patients with ongoing infection(s) other than HIV. 2. Prior or current pancreatitis or history of alcohol abuse. 3. Ongoing neuropathy and history of more than grade 1 neuropathy. 4. History of mutations to more than one class of anti-retroviral drugs or switched drugs more than once due to failure. 5. Sun or solarium exposure at the immunizing sites one month before or during the trial. 6. Cortisone treatment, systemic or local at the immunizing sites, one month before or during the trial. 7. Patients with signs of autoimmune diseases 8. Patients with creatinine > 2mg/dl, Hb < 12g/dl, leukocytes < 3,000ul, platelets <150,000/ul and LFT > 5x upper limit of normal 9. Patients on any immune modulating or investigational drug 10. Anamnestic allergy to kanamycin, plasmid gene products |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Sweden | South Hospital | Stockholm |
Lead Sponsor | Collaborator |
---|---|
Swedish Institute for Infectious Disease Control | European Union, Läkare mot AIDS Forskningsfond, The Swedish Research Council |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and feasibility | The safety and feasibility of dermal HIV-1 DNA vaccination will be evaluated by recording all medical events. They will be graded as to their seriousness, severity and relationship to the immunization. Plasma HIV-1 RNA levels and T-cell levels will be closely monitored. In addition to this the patient's individual experience and quality of life will be assessed. | Yes | |
Secondary | Treatment effects | To evaluate whether dermal HIV-1 DNA vaccination can prolong periods without treatment in HIV-infected individuals. This will be evaluated by structured treatment interruption with close monitoring of HIV viral load and CD4+ T cell counts | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01968551 -
Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
|
Phase 3 | |
Terminated |
NCT03708289 -
Body Composition, Bone Health and Hormonal Status in HIV-1-infected Individuals
|
||
Completed |
NCT02547844 -
Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla
|
Phase 4 | |
Terminated |
NCT01345630 -
Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1
|
Phase 3 | |
Completed |
NCT00807443 -
Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1
|
Phase 2 | |
Terminated |
NCT01173276 -
Intrauterine Insemination In HIV-Discordant Couples
|
N/A | |
Withdrawn |
NCT00340223 -
HLA-B35 Alleles and AIDS
|
N/A | |
Completed |
NCT00097006 -
Retrovirus Epidemiology Donor Study-II (REDS-II)
|
N/A | |
Completed |
NCT02217904 -
A Study of Islatravir (MK-8591) in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003)
|
Phase 1 | |
Completed |
NCT00772902 -
ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial
|
Phase 4 | |
Completed |
NCT04006704 -
Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets
|
Phase 1 | |
Terminated |
NCT03060629 -
A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa
|
Phase 2 | |
Recruiting |
NCT00981695 -
Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1-infected Mothers
|
Phase 1/Phase 2 | |
Completed |
NCT01084343 -
Investigation of the Safety of an HIV-1 Vaccine Given Intra-muscularly and Intra-nasally to Healthy Female Subjects
|
Phase 1 | |
Completed |
NCT00982579 -
Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1/2-uninfected Mothers
|
Phase 1 | |
Completed |
NCT00665847 -
TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents
|
Phase 2 | |
Completed |
NCT00098293 -
Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine
|
Phase 3 | |
Completed |
NCT05944848 -
A Study of CL-197 Capsules in Healthy Participants
|
Phase 1 | |
Completed |
NCT00479999 -
Phase 1 Safety Study of Two Experimental HIV Vaccines
|
Phase 1 | |
Completed |
NCT01274780 -
Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients
|
Phase 4 |